Literature DB >> 7523849

Evidence for an extra-cellular function for protein kinase A.

S Shaltiel1, I Schvartz, B Korc-Grodzicki, T Kreizman.   

Abstract

In addition to its intra-cellular functions, cAMP-dependent protein kinase (PKA) may well have an extra-cellular regulatory role in blood. This suggestion is based on the following experimental findings: (a) Physiological stimulation of blood platelets brings about a specific release of PKA, together with its co-substrates ATP and Mg++; (b) In human serum, an endogenous phosphorylation of one protein (p75, M(r) 75 kDa) occurs; this phosphorylation is enhanced by addition of cAMP and blocked by the Walsh-Krebs specific PKA inhibitor; (c) No endogenous phosphorylation of p75 occurs in human plasma devoid of platelets, but the selective labeling of p75 can be reproduced by adding to plasma the pure catalytic subunit of PKA; (d) p75 was shown to be vitronectin (V), a multifunctional protein implicated in processes associated with platelet activation, and thus a protein whose function may require modulation for control; (e) The phosphorylation of vitronectin occurs at one site (Ser378) which, at physiological pH, is buried in its two-chain form (V65 + 10) but it becomes 'exposed' in the presence of glycosaminoglycans (GAGs) e.g. heparin or heparan sulfate. Such a transconformation may be used for targeting the PKA phosphorylation to vitronectin molecules bound to GAGs, for example in the extracellular matrix or on cell surfaces; (f) From the biochemical point of view (Km values and physiological concentrations) the phosphorylation of vitronectin can take place at the locus of a hemostatic event; (g) The phosphorylation of Ser378 in vitronectin alters its function, since it significantly reduces its ability to bind the inhibitor-1 of plasminogen activator(s) (PAI-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7523849     DOI: 10.1007/978-1-4615-2600-1_26

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  58 in total

1.  Characterization and identification of heparin-induced nonopioid-binding sites for beta-endorphin in human plasma.

Authors:  A Hildebrand; L Schweigerer; H Teschemacher
Journal:  J Biol Chem       Date:  1988-02-15       Impact factor: 5.157

2.  Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. Use in mapping the PAI-1 binding site.

Authors:  Z Gechtman; R Sharma; T Kreizman; M Fridkin; S Shaltiel
Journal:  FEBS Lett       Date:  1993-01-11       Impact factor: 4.124

3.  cAMP export and its regulation by prostaglandin A1.

Authors:  L L Brunton; L E Heasley
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

4.  Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.

Authors:  E M Salonen; A Vaheri; J Pöllänen; R Stephens; P Andreasen; M Mayer; K Danø; J Gailit; E Ruoslahti
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

5.  Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma.

Authors:  B Wiman; A Almquist; O Sigurdardottir; T Lindahl
Journal:  FEBS Lett       Date:  1988-12-19       Impact factor: 4.124

6.  Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.

Authors:  B Dahlbäck; E R Podack
Journal:  Biochemistry       Date:  1985-04-23       Impact factor: 3.162

7.  Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1.

Authors:  D Chain; T Kreizman; H Shapira; S Shaltiel
Journal:  FEBS Lett       Date:  1991-07-22       Impact factor: 4.124

8.  Evidence for ecto-protein kinase activity that phosphorylates Kemptide in a cyclic AMP-dependent mode.

Authors:  D Kübler; W Pyerin; O Bill; A Hotz; J Sonka; V Kinzel
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

9.  Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man.

Authors:  A E Broadus; N I Kaminsky; J G Hardman; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

View more
  4 in total

1.  The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.

Authors:  Z Gechtman; A Belleli; S Lechpammer; S Shaltiel
Journal:  Biochem J       Date:  1997-07-15       Impact factor: 3.857

2.  Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease.

Authors:  Sathish Kumar; Jochen Walter
Journal:  Aging (Albany NY)       Date:  2011-08       Impact factor: 5.682

3.  PI3K activation prevents Aβ42-induced synapse loss and favors insoluble amyloid deposit formation.

Authors:  Mercedes Arnés; Ninovska Romero; Sergio Casas-Tintó; Ángel Acebes; Alberto Ferrús
Journal:  Mol Biol Cell       Date:  2019-12-26       Impact factor: 4.138

4.  Novel Flavivirus Attenuation Markers Identified in the Envelope Protein of Alfuy Virus.

Authors:  Daniel Westlake; Helle Bielefeldt-Ohmann; Natalie A A Prow; Roy A A Hall
Journal:  Viruses       Date:  2021-01-20       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.